• Miscellaneous musculoskeletal disorders

Evrysdi Generic Name & Formulations

General Description

Risdiplam 60mg; pwd for oral soln (providing 0.75mg/mL) after constitution; contains mannitol, sucralose; strawberry flavor.

Pharmacological Class

Survival motor neuron 2 (SMN2) splicing modifier.

How Supplied

Bottle (80mL)—1 (w. adapter, oral syringes)


Generic Availability


Evrysdi Indications


Spinal muscular atrophy (SMA).

Evrysdi Dosage and Administration

Adults and Children

Must be administered immediately after drawn up into the oral syringe. Take once daily after a meal at same time each day. May be given via nasogastric or gastrostomy tube if unable to swallow. <2months: 0.15mg/kg. 2months–<2yrs: 0.2mg/kg. ≥2yrs (<20kg): 0.25mg/kg; (≥20kg): 5mg. Breastfed infants: administer after breastfeeding; do not mix with formula or milk.

Evrysdi Contraindications

Not Applicable

Evrysdi Boxed Warnings

Not Applicable

Evrysdi Warnings/Precautions


Avoid inhalation and direct contact with skin or mucous membranes with dry powder and constituted solution. Hepatic impairment: avoid. Pregnancy: exclude status prior to initiation. Advise females of reproductive potential to use effective contraception during and for ≥1 month after the last dose. Possible male infertility. Nursing mothers.

Evrysdi Pharmacokinetics

See Literature

Evrysdi Interactions


Avoid concomitant with MATE substrates (eg, metformin); if unavoidable, monitor for drug-related toxicities; consider dose reduction of substrate.

Evrysdi Adverse Reactions

Adverse Reactions

Late-onset: fever, diarrhea, rash; Infantile-onset: also upper respiratory tract infection, pneumonia, constipation, vomiting.

Evrysdi Clinical Trials

See Literature

Evrysdi Note

Not Applicable

Evrysdi Patient Counseling

See Literature